TriangleStandard of Care Neoadjuvant… (NCT04677816)
Standard of Care Neoadjuvant Chemotherapy (NAC) trial for Triple Negative Breast Cancer (NCT04677816). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with operable breast cancer meeting the study’s triple-negative criteria, before preoperative chemotherapy. Participants are grouped by vitamin D levels.
The idea: deficient patients take oral vitamin D3, 50,000 international units weekly for 20 weeks, alongside chemotherapy. Activated vitamin D binds receptors that change gene activity. Researchers test whether supplementation affects complete tumor clearance at surgery. Patients with sufficient vitamin D form an observational group; this is not random assignment.
This phase 2 study plans 50 patients. Emily Douglas leads at Wake Forest, Winston-Salem, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.